Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.49 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473680 | 0.93 | TFPI (0.51) | TFPIVIPR1VIPR2BACE1 | |
| SCHEMBL30159262 | 0.90 | NPY4R (0.48) | TFPIVIPR1VIPR2 | |
| SCHEMBL29473688 | 0.89 | TFPI (0.51) | TFPIVIPR1VIPR2 | |
| SCHEMBL30681588 | 0.89 | VIPR2 (0.49) | TFPIVIPR1VIPR2IL23R | |
| SCHEMBL29475967 | 0.89 | VIPR1 (0.50) | TFPIVIPR1VIPR2BACE1 | |
| SCHEMBL30768183 | 0.89 | BACE1 (0.53) | TFPIBACE1CTSD | |
| SCHEMBL29593786 | 0.89 | VIPR1 (0.48) | TFPIVIPR1VIPR2 | |
| SCHEMBL29473696 | 0.88 | VIPR1 (0.52) | TFPIVIPR1VIPR2KISS1R | |
| SCHEMBL38659416 | 0.88 | BACE1 (0.54) | TFPIVIPR1VIPR2BACE1CTSD | |
| SCHEMBL30605187 | 0.88 | TFPI (0.52) | TFPIVIPR1VIPR2BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5486595-A | Tumor necrosis factor inhibitors | CENTECOR, INC. (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | disclosed |